Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Weinsaft

Nuclear Cardiology New York, NY Medical Doctor

NPI 1609964972 CMS profile 255037

520 E 70Th St-Starr 4, New York, NY 10021

Open in the dashboard

General payments

$10,482

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$97,741 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Jonathan Weinsaft of New York, NY is reported in the CMS Open Payments database as having received $10,482 across 17 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $97,741 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $482 5
2024 General $6,915 5
2023 General $31 1
2022 General $1,200 1
2021 General $1,760 3
2020 General $26 1
2019 General $68 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Weinsaft
  • Nuclear Cardiology median
  • Middle half of Nuclear Cardiology
  • National median

In program year 2025, general payments to Jonathan Weinsaft were reported at $482. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.

Show as a table
Year Jonathan Weinsaft Nuclear Cardiology median Middle half National median
2019 $68 $552 $91–$1,768 $163
2020 $26 $204 $61–$1,106 $114
2021 $1,760 $354 $99–$886 $132
2022 $1,200 $506 $101–$1,186 $149
2023 $31 $545 $148–$1,432 $160
2024 $6,915 $484 $131–$1,430 $164
2025 $482 $434 $138–$985 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Idorsia Pharmaceuticals US Inc $6,473 2 payments
  2. Ge Healthcare $3,017 6 payments
  3. HeartFlow, Inc. $295 3 payments
  4. Abbott Laboratories $291 2 payments
  5. Boston Scientific Corporation $166 1 payment
  6. Edwards Lifesciences Corporation $145 1 payment
  7. Canon Medical Systems USA, Inc. $68 1 payment
  8. Novartis Pharmaceuticals Corporation $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,400 5 payments
  2. Food and Beverage $1,049 11 payments
  3. Travel and Lodging $33 1 payment
Products named General payments · program years 2019–2025
  1. Tryvio $6,473 2 payments
  2. FFRct $295 3 payments
  3. FARAWAVE $166 1 payment
  4. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $148 1 payment
  5. SAPIEN 3 Ultra RESILIA $145 1 payment
  6. THORATEC HEARTMATE 3 $144 1 payment
  7. LEQVIO $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$296,481

Of which drugs: $9,192

Medicare patients

690

Average age 75

Services billed

77,767

319 women, 371 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Arthritis 53%
Heart failure 40%
Diabetes 36%
Atrial fibrillation 33%
Chronic kidney disease 27%
Cancer 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 281 75,571 $7,247
Injection, regadenoson, 0.1 mg J2785 Office 104 416 $1,755
Injection, aminophyllin, up to 250 mg J0280 Office 16 16 $118

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nuclear Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record